Matinas BioPharma regains NYSE American continued listing compliance

Matinas BioPharma Holdings, Inc.

Received notification on March 21, 2024, resolving low selling price deficiency under Section 1003(f)(v).
Common stock demonstrated sustained price improvement, curing the non-compliance.
'.BC' indicator discontinued at market open on March 22, 2024; removed from noncompliant issuers list.
NYSE American confirmed continued listing standard is now satisfied.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.